<DOC>
	<DOC>NCT01907724</DOC>
	<brief_summary>The purpose of this study is to evaluate the potential for a PK drug-drug interaction when IDX719, simeprevir, TMC647055 and low-dose ritonavir (RTV) are administered in combination. Safety and tolerability will also be assessed.</brief_summary>
	<brief_title>Drug-Drug Interaction Between IDX719, Simeprevir, TMC647055 and Ritonavir When Administered in Combination in Healthy Participants (MK-1894-007)</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Hepatitis C, Chronic</mesh_term>
	<mesh_term>Ritonavir</mesh_term>
	<mesh_term>Simeprevir</mesh_term>
	<criteria>Agrees to use a double method of birth control (one of which must be a barrier) from Screening through at least 90 days after the last dose of the study drug Male participants agree not to donate sperm from Day 1 through 90 days after the last dose of study drug Is pregnant or breastfeeding Has another clinically significant medical conditions or laboratory abnormality(s)</criteria>
	<gender>All</gender>
	<minimum_age>19 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>January 2016</verification_date>
	<keyword>Chronic hepatitis C</keyword>
	<keyword>Hepatitis C virus</keyword>
	<keyword>HCV</keyword>
</DOC>